{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:45:23Z","timestamp":1788050723330,"version":"build-2784847793"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijrobp.2025.05.075","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:24:59Z","timestamp":1749756299000},"page":"742-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Once-Daily Postmastectomy Radiation Therapy Confers Excellent Locoregional Control for Inflammatory Breast Cancer"],"prefix":"10.1016","volume":"123","author":[{"given":"Kate R.","family":"Pawloski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Diskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif J.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-251X","authenticated-orcid":false,"given":"Audree B.","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.05.075_bib0001","unstructured":"National Comprehensive Cancer Network. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed April 25, 2024."},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0002","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.7150\/jca.23969","article-title":"International consensus on the clinical management of inflammatory breast cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference","volume":"9","author":"Ueno","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0003","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0005","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0006","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2014.55.1978","article-title":"Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: An analysis of treatment and survival trends from the National Cancer Database","volume":"32","author":"Rueth","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0007","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-017-4119-6","article-title":"Inflammatory breast cancer in the Netherlands; improved survival over the last decades","volume":"162","author":"van Uden","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0008","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/cncr.31757","article-title":"Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?","volume":"124","author":"Romanoff","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0009","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12885-021-07855-z","article-title":"Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: A SEER population-based analysis","volume":"21","author":"Jiao","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clbc.2013.04.002","article-title":"Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy","volume":"13","author":"Saigal","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0011","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1634\/theoncologist.2011-0196","article-title":"Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer","volume":"16","author":"Li","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0012","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/bcr2225","article-title":"Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): Analysis of 2,014 IBC patient cases from the California Cancer Registry","volume":"11","author":"Zell","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0013","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.ijrobp.2009.06.042","article-title":"Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era","volume":"77","author":"Damast","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0014","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.clbc.2017.10.003","article-title":"Influence of biologic subtype of inflammatory breast cancer on response to neoadjuvant therapy and cancer outcomes","volume":"18","author":"Hieken","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2018-0677","article-title":"Inflammatory breast cancer outcomes by breast cancer subtype: A population-based study","volume":"15","author":"Wu","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0016","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1245\/s10434-015-4469-4","article-title":"Inflammatory breast cancer: Patterns of failure and the case for aggressive locoregional management","volume":"22","author":"Warren","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0017","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1245\/s10434-017-5903-6","article-title":"The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer","volume":"24","author":"Nakhlis","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0018","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0019","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/bjs.11469","article-title":"Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database","volume":"107","author":"Kupstas","year":"2020","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0020","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clbc.2016.02.004","article-title":"Inflammatory TNBC breast cancer: Demography and clinical outcome in a large cohort of patients with TNBC","volume":"16","author":"Biswas","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0021","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/1097-0142(19951201)76:11<2286::AID-CNCR2820761116>3.0.CO;2-L","article-title":"Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy","volume":"76","author":"Thomas","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0022","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002800050664","article-title":"Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M. D. Anderson Cancer Center","volume":"40","author":"Ueno","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0023","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.prro.2019.05.011","article-title":"Excellent locoregional control in inflammatory breast cancer with a personalized radiation therapy approach","volume":"9","author":"Stecklein","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0024","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1245\/s10434-017-5952-x","article-title":"Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery","volume":"24","author":"Rosso","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0025","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ijrobp.2014.05.004","article-title":"Postmastectomy radiation therapy for inflammatory breast cancer: Is more better?","volume":"89","author":"Woodward","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0026","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1245\/s10434-023-13906-5","article-title":"Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy","volume":"30","author":"Adesoye","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0027","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0028","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ijrobp.2014.01.054","article-title":"Once-daily radiation therapy for inflammatory breast cancer","volume":"89","author":"Brown","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0029","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijrobp.2024.04.010","article-title":"Impact of radiation therapy modalities on loco-regional control in inflammatory breast cancer","volume":"120","author":"Rog\u00e9","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0030","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","article-title":"Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer","volume":"18","author":"DeSnyder","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0031","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer","volume":"7","author":"Hidar","year":"2009","journal-title":"Int J Surg"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0032","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02573060","article-title":"Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer","volume":"9","author":"Stearns","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0033","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000512202","article-title":"Sentinel lymph node biopsy may prevent unnecessary axillary dissection in patients with inflammatory breast cancer who respond to systemic treatment","volume":"16","author":"Karanlik","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0034","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6438635","article-title":"The impact of locoregional therapy in nonmetastatic inflammatory breast cancer: A population-based study","volume":"2018","author":"Muzaffar","year":"2018","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijrobp.2008.01.039","article-title":"Locoregional treatment outcomes after multimodality management of inflammatory breast cancer","volume":"72","author":"Bristol","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0036","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jamcollsurg.2021.04.016","article-title":"Reconstruction in women with T4 breast cancer after neoadjuvant chemotherapy: When is it safe?","volume":"233","author":"Pawloski","year":"2021","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0037","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/cco-21-113","article-title":"Contemporary surgical management of inflammatory breast cancer: A narrative review","volume":"10","author":"Adesoye","year":"2021","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0038","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1245\/s10434-022-12144-5","article-title":"Long-term oncologic outcomes in patients with inflammatory breast cancer with supraclavicular nodal involvement","volume":"29","author":"Cobb","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0039","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijrobp.2022.09.065","article-title":"Outcomes of breast cancer patients with high volume of residual disease following neoadjuvant chemotherapy","volume":"115","author":"Zhang","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0040","unstructured":"Tadros AB. A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer. ClinicalTrials.gov identifier: NCT05412225. Published April 12, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05412225?term=tadros%20a&rank=2. Accessed May 13, 2024."},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0041","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","article-title":"Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes","volume":"23","author":"Cristofanilli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0042","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-012-2233-z","article-title":"Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer","volume":"136","author":"Lips","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2021.11.017","article-title":"Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis","volume":"61","author":"O\u2019Connor","year":"2022","journal-title":"Breast Edinb Scotl"},{"key":"10.1016\/j.ijrobp.2025.05.075_bib0044","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-022-06813-y","article-title":"Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?","volume":"197","author":"Mamtani","year":"2023","journal-title":"Breast Cancer Res Treat"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625005929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625005929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:38:41Z","timestamp":1762951121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625005929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0360301625005929"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.075","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-Daily Postmastectomy Radiation Therapy Confers Excellent Locoregional Control for Inflammatory Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.05.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}